No psychiatric disorder lifetime | At least one current psychiatric disorder | New-onset psychiatric disorders | Significant suicide risk | |
N=131 | N=36 | N=29 | N=9 | |
Baseline characteristics | ||||
Age (years) (m (SD)) | 57.2 (14.0) | 56.2 (9.4) | 54.9 (9.2) | 56.9 (7.2) |
Women (n (%)) | 41 (31.3) | 22 (61.1)** | 18 (62.1)** | 6 (66.7) |
BMI (m (SD)) | 28.0 (7.8) | 28.3 (4.9) | 28.2 (5.3) | 27.7 (4.3) |
ICU stay (n (%)) | 78 (59.5) | 12 (33.3)** | 9 (31.0) | 3 (33.3) |
Intubation (n (%)) | 40 (30.5) | 6 (16.7) | 4 (13.8) | 0 (0.0) |
C-PAP (n (%)) | 35 (26.7) | 7 (19.4) | 6 (20.7) | 2 (22.2) |
Length of hospital stay (days) (m (SD)) | 22.6 (16.0) | 19.6 (16.5) | 18.2 (15.6) | 14.7 (17.9) |
Long COVID complaints | ||||
Number of long COVID complaints (m (SD)) | 1.35 (1.48) | 2.47 (1.30)*** | 2.41 (1.32)** | 2.67 (1.32)* |
Fatigue (n (%)) | 50 (40.7)) | 23 (63.9)** | 19 (65.5)* | 6 (66.7) |
Respiratory complaints (n (%)) | 49 (37.4) | 25 (69.4)** | 19 (65.5)* | 7 (77.8)* |
Cognitive complaints (n (%)) | 23 (17.6) | 17 (47.2)** | 14 (48.3)** | 6 (66.7)** |
Muscle weakness (n (%)) | 14 (12.4) | 3 (8.3) | 2 (6.9) | 0 (0.0) |
Persistent pain (n (%)) | 12 (10.5) | 4 (11.1) | 4 (13.8) | 2 (22.2) |
Headache (n (%)) | 9 (7.9) | 4 (11.1) | 2 (6.9) | 1 (11.1) |
Paraesthesia (n (%)) | 26 (22.8) | 8 (22.2) | 8 (27.6) | 2 (22.2) |
Persistent anosmia (n (%)) | 10 (8.8) | 5 (13.9) | 2 (6.9) | 1 (11.1) |
Long COVID objective criteria | ||||
MoCA <26 (n (%)) | 93 (66.0) | 22 (61.4) | 17 (58.6) | 6 (66.6) |
CT scan abnormalities | 86 (67.2) | 14 (41.2)* | 12 (41.4)* | 2 (22.2)* |
*P<0.05; **p<0.01; ***p<0.001 (bold: statistically significant (p<0.05) differences with the control group (patients without any lifetime psychiatric disorder) in bivariate analyses).
BMI, body mass index; C-PAP, continuous positive airway pressure; HBP, high blood pressure; ICU, intensive care unit; m, mean; MoCA, Montreal Cognitive Assessment.